试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
编号:NCT03292731登记状态:提前终止企业 / 申办者:Steve N. Caritis, MD
药物 / 成分:17-Hydroxyprogesterone caproate 250mg or 500 mg.、Safety study of 500 mg dose.
登记的停止原因(原文):grant funding cycle ended
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
编号:NCT03679624登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Ibrutinib、Daratumumab
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Spironolactone Versus Prednisolone in DMD
编号:NCT03777319登记状态:提前终止企业 / 申办者:Kevin Flanigan
药物 / 成分:Spironolactone、Prednisolone
登记的停止原因(原文):Inability to recruit participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Natural Berry Extract Treatment of Hemangiomas
编号:NCT04020419登记状态:提前终止企业 / 申办者:Gayle Gordillo
药物 / 成分:PediaBerry
登记的停止原因(原文):Study ending early due to program transferring to another site.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
编号:NCT04308785登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Atezolizumab、Tiragolumab、Placebo
登记的停止原因(原文):The sponsor's decision was based on the negative results of SKYSCRAPER-02.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
编号:NCT04343235登记状态:提前终止企业 / 申办者:Wright State University
药物 / 成分:furosemide、labetalol
登记的停止原因(原文):Challenges with enrollment; primary investigator left the institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
编号:NCT04699461登记状态:提前终止企业 / 申办者:ADC Therapeutics S.A.
药物 / 成分:Loncastuximab Tesirine、Idelalisib
登记的停止原因(原文):Administrative decision (not due to safety reason)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
编号:NCT04931862登记状态:提前终止企业 / 申办者:Wave Life Sciences USA, Inc.
药物 / 成分:WVE-004、Placebo
登记的停止原因(原文):Despite robust, sustained reductions in poly(GP), no clinical benefit was seen at 24 weeks, and reductions in poly(GP) were not associated with stabilization in functional outcomes. Based on these data, Wave decided to stop development of WVE-004.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
编号:NCT04958434登记状态:提前终止企业 / 申办者:Transcenta Therapeutics (Hangzhou) Co., Ltd.
药物 / 成分:TST005
登记的停止原因(原文):Corporate Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-23
Medrol Dosepak Taper for Delayed Post-op Recovery After TKA
编号:NCT05113901登记状态:提前终止企业 / 申办者:Rush University Medical Center
药物 / 成分:Methylprednisolone、Placebo
登记的停止原因(原文):Extremely low participation, decided to focus on similar study instead
查看官方原始记录 ↗